NEW YORK,
Aug. 21,
2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.
(NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in
the development of targeted radiotherapies, today details two
abstracts accepted for oral and poster presentation at the upcoming
European Association of Nuclear Medicine (EANM) 2023 Congress,
which will be held in Vienna,
September 9-13, 2023. The EANM
oral presentation, reflecting the potentially paradigm changing
Iomab-B SIERRA data in facilitating transplants for people with AML
who are currently not considered for transplant, represents the
fifth oral presentation at prestigious medical conferences globally
in 2023 including TCT, EBMT, SNMMI, and EHA.
Details of the EANM oral presentation:
Presentation Title: "Safety and dosimetry evaluation of
personalized dose I131-apamistamab prior to HCT in the phase 3
SIERRA trial for patients with relapsed/refractory acute myeloid
leukemia (R/R AML)"
Session: Theranostics Track - Oncology & Theranostics
Committee / EARL - Featured Session: Old but Novel Techniques
Date and Time: September 10,
3:00pm CET
Details of the EANM e-poster presentation:
All e-posters will be accessible for viewing for the entirety of
the conference.
e-Poster Title: Feasibility of high-dose targeted
radiation with I131-apamistamab in patients with
relapsed/refractory AML: Dosimetry and radiation safety experience
from the phase 3 SIERRA trial
e-Poster Number: EP-0608
Session Title: C: Therapy Clinical Study -> C1
Oncological Therapy Clinical Study -> C15 Other Oncological
Treatments
About Actinium
Actinium develops targeted radiotherapies to meaningfully
improve survival for people who have failed existing oncology
therapies. Advanced pipeline candidates Iomab-B (pre-BLA), an
induction and conditioning agent prior to bone marrow transplant,
and Actimab-A (National Cancer Institute CRADA pivotal development
path), a therapeutic, have demonstrated potential to extend
survival outcomes for people with relapsed and refractory acute
myeloid leukemia. Actinium plans to advance Iomab-B for other
blood cancers and next generation conditioning candidate Iomab-ACT
to improve cell and gene therapy outcomes. Actinium's technology
platform is the basis for collaborations with Astellas Pharma
for solid tumors, AVEO Oncology/LG Chem Life Sciences for HER3
solid tumors, and EpicentRx for its CD47 targeting agent, and
several internal programs in solid tumors. Actinium holds more than
200 patents and patent applications.
For more information, please visit:
https://www.actiniumpharma.com/
Forward-Looking Statements
This press release may contain projections or other
"forward-looking statements" within the meaning of the
"safe-harbor" provisions of the private securities litigation
reform act of 1995 regarding future events or the future financial
performance of the Company which the Company undertakes no
obligation to update. These statements are based on management's
current expectations and are subject to risks and uncertainties
that may cause actual results to differ materially from the
anticipated or estimated future results, including the risks and
uncertainties associated with preliminary study results varying
from final results, estimates of potential markets for drugs under
development, clinical trials, actions by the FDA and other
governmental agencies, regulatory clearances, responses to
regulatory matters, the market demand for and acceptance of
Actinium's products and services, performance of clinical research
organizations and other risks detailed from time to time in
Actinium's filings with the Securities and Exchange Commission (the
"SEC"), including without limitation its most recent annual report
on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms
8-K, each as amended and supplemented from time to time.
Contact:
Matthew Beck
Vice President Investor Relations & Communications
mbeck@actiniumpharma.com
(917) 415-1750
View original content to download
multimedia:https://www.prnewswire.com/news-releases/actinium-pharma-highlights-abstracts-accepted-for-oral-and-poster-presentation-at-the-eanm-2023-congress-301905016.html
SOURCE Actinium Pharmaceuticals, Inc.